Erasca, Inc. Shareholders' Equity
Erasca, Inc. (ERAS) had Shareholders' Equity of $361.87 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $361.87M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $393.53M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $325.17M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $347.89M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $361.87M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $393.53M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $325.17M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $347.89M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $372.26M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $399.50M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $423.50M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $450.04M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $451.09M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $288.41M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $316.69M 10-K · filed 2026-03-12 |
| 2023-09-30 | $338.98M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $362.70M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $386.45M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $411.85M 10-K · filed 2025-03-20 |
| 2022-09-30 | $365.32M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $395.07M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $424.66M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $456.53M 10-K · filed 2024-03-27 |
| 2021-09-30 | $482.99M 10-Q · filed 2022-11-09 |
| 2021-06-30 | -$150.00M 10-Q · filed 2022-11-09 |
| 2021-03-31 | -$129.26M 10-Q · filed 2022-11-09 |
| 2020-12-31 | -$113.98M 10-K · filed 2023-03-23 |
| 2020-09-30 | -$52.82M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$42.55M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$37.18M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$13.60M 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |